CD274 and small cell lung carcinoma: The phase Ib KEYNOTE-028 trial showed favorable efficacy and tolerable safety of pembrolizumab in treating patients with relapsed ED-SCLC and PD-L1 expression on ≥ 1% of tumor and stromal cells [71].